Skip to main content
OpenTrials
Completed

NCT Number: NCT04583293

Acute KIDnEy Injury in CoviD-19

This is a prospective observational parallel group cohort study that will aim to recruit 220 participants who were admitted to the hospital with COVID-19 between 1st March 2020 and 30th June 2020 (Group A - 110 participants who had COVID-19 with AKI; Group B - 110 participants who had COVID-19 without AKI). Data from groups A and B will be compared with AKI and non-AKI groups from an existing study database (ARID study, n=1125) who were recruited before the outbreak of the COVID-19 pandemic (recruitment 2013-2016) and who have all completed at least three years of follow up. Participants who have recovered from COVID-19 will be matched for analysis to participants from the ARID study for AKI status, baseline estimated glomerular filtration rate (eGFR) stage, age (± 5 years) and presence of diabetes. Potential participants will receive a letter of invitation along with a comprehensive participant information sheet (PIS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospitals of Derby and Burton NHS Foundation Trust

Derby, Derbyshire, DE22 3DT, United Kingdom

About this study

After the participants have read and understand the PIS, and had sufficient time (at least 24 hours) to consider their participation in this study, the investigators will ask them to sign a consent form, which shows their willingness to take part. The investigators will then collect information from their medical records about their hospital admission with COVID-19, including their age, ethnicity, medical conditions, length of hospital stay, tablets or any other treatments they received, as well as details of their stay in the intensive care unit.

For the two groups - COVID AKI and COVID non-AKI, telephone follow-up with a study questionnaire will be performed at recruitment, 6-9 months and 12-15 months after hospital discharge. The study questionnaire will include the following:

  • Details of any medical event and date of medical event since last study follow-up.
  • Details of any hospital re-admission.
  • Details of current medication.

In addition, at the same time points, participants will be asked to attend their general practitioner surgery or other clinic to have simple clinical measurements (height, weight and blood pressure), blood and urine tests.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients greater or equal to 18 years of age.
  • Swab results positive for SARS-CoV-2.
  • Patients admitted to the hospital for ≥24hrs.

Exclusion criteria

  • Paediatric patients as defined by age of <18 years of age.
  • Patients >90 years of age.
  • Swab results negative for SARS-CoV-2.
  • Patients on haemodialysis or peritoneal dialysis, pre-existing CKD stage 5 (eGFR <15ml/min/1.73m2), solid organ transplant.
  • Inability/refusal to give informed consent to participate.
  • Death during the same hospital admission that AKI occurred.

Treatment and study plan

No intervention

Other

This study does not involve any intervention or new treatment.

Primary outcomes

  1. Incidence of kidney disease progression at 12 months.

    Time frame: 12 months after hospital discharge.

    Kidney disease progression will be defined as a decline in estimated glomerular filtration rate (eGFR; ml/min/1.73m2) of ≥30%

Secondary outcomes

  1. Incidence of albuminuria at 6-9 months.

    Time frame: 6-9 months after hospital discharge.

    Albuminuria will be defined as a urine albumin to creatinine ratio (UACR) of >30mg/mmol.

  2. Incidence of albuminuria at 12-15 months.

    Time frame: 12-15 months after hospital discharge.

    Albuminuria will be defined as a urine albumin to creatinine ratio (UACR) of >30mg/mmol.

  3. Incidence of combined kidney disease progression and albuminuria at 6-9 months.

    Time frame: 6-9 months after hospital discharge.

    Combined kidney disease progression outcome of ≥30% decline in eGFR (ml/min.1.73m2) and/or albuminuria (UACR>30mg/mmol).

  4. Incidence of combined kidney disease progression and albuminuria at 12-15 months.

    Time frame: 12-15 months after hospital discharge.

    Combined kidney disease progression outcome of ≥30% decline in eGFR (ml/min.1.73m2) and/or albuminuria (UACR>30mg/mmol).

  5. Factors associated with all-cause mortality at 6-9 months.

    Time frame: 6-9 months after hospital discharge.

    Multi-variable Cox proportional hazards models will be used to assess the factors associated with all-cause mortality

  6. Factors associated with all-cause mortality at 12-15 months.

    Time frame: 12-15 months after hospital discharge.

    Multi-variable Cox proportional hazards models will be used to assess the factors associated with all-cause mortality

  7. Incidence of hospital readmissions at 6-9 months

    Time frame: 6-9 months after hospital discharge.

    Number of hospital readmissions

  8. Incidence of hospital readmissions at 12-15 months

    Time frame: 12-15 months after hospital discharge.

    Number of hospital readmissions

Sponsors and collaborators

Lead sponsor

University Hospitals of Derby and Burton NHS Foundation Trust

Other

Registry information

Official study title

Long-term Outcomes After Acute Kidney Injury in Coronavirus Disease (COVID-19)

Acronym: AIDED

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Oct 12, 2020
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.